Literature DB >> 19795615

[Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to front line antituberculosis drugs and comparison with the radiometric BACTEC 460 TB method].

Melda Sinirtaş1, Cüneyt Ozakin, Suna Gedikoğlu.   

Abstract

The performance of the fully automated BACTEC MGIT 960 (Becton Dickinson, Cockeysville, Md.) system for susceptibility testing of Mycobacterium tuberculosis to critical concentrations of 4 major antituberculosis drugs [streptomycin (STR), isoniazid (INH), rifampin (RIF) and ethambutol (EMB)] was evaluated with 100 clinical isolates and compared to that of the radiometric BACTEC 460 TB (Becton Dickinson, Sparks, Md.) system. The results of BACTEC 960 MGIT, which are not compatible with BACTEC 460 TB, were re-evaluated according to the results obtained. The discordance was 2.25% at the critical concentrations of both systems. After the reproducibility testing, the discordance between 2 systems reduced to 1.25% and the concordance increased to 98.75%. In our study, no very major error was observed; major error was detected as 2.25% (STR 2, INH 4, RIF 2 and EMB 1) in the 1st trial, and 1.25% (INH 3, RIF 2) in the 2nd trial. When BACTEC 460 TB has been compared with BACTEC 960 MGIT, the overall specificity was 100% in all tests, the sensitivity was 95.6-98.9% in the initial testing, however, the sensitivity changed to 96.7-100% after the reproducibility testing. It was concluded that there was no statistically significant disconcordance between the two test systems. Thus BACTEC MGIT 960 might be an alternative to BACTEC 460 TB for susceptibility testing of antituberculosis agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19795615

Source DB:  PubMed          Journal:  Mikrobiyol Bul        ISSN: 0374-9096            Impact factor:   0.622


  1 in total

1.  Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.

Authors:  Saumu Pazia Juma; Athanasia Maro; Suporn Pholwat; Stellah G Mpagama; Jean Gratz; Alphonse Liyoyo; Eric R Houpt; Gibson S Kibiki; Blandina T Mmbaga; Scott K Heysell
Journal:  BMC Infect Dis       Date:  2019-02-07       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.